Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...
Announces that the Company's virtual Annual General Meeting of Shareholders will be webcast on Wednesday, ...
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...
Today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to ...
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL)...
Announced today that Northwestern University has enrolled the first patient in the pivotal Phase III ...
Designed to assess the impact of CardiolRxâ„¢ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase...
Announced today its year-end 2024 update on operations following the filing of its audited Financial ...
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...
Announced today the publication of research in the Journal of the American College of Cardiology: Basic ...